Here's a snapshot of some recent portfolio activity:
UTEST, the early-stage technology accelerator MI runs in partnership with the University of Toronto, was cited in the Wall Street Journal as part of what makes Toronto the best place to build a start-up in Canada and the eighth-best place in the world. Applications for UTEST's the third cohort are open until Thursday, April 17, 2014.
OtoSim Inc. placed first out of 20 companies in the Venture Pitch competition at the Fundica Funding Roadshow for ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Mount Sinai’s Lunenfeld-Tanenbaum Research Institute has developed a new test that could make a big difference to men facing infertility.
A study published in a leading international journal, Science Translational Medicine, details the discovery of a key biomarker that can pinpoint the cause of infertility without the need for invasive surgery.
This story was covered by BBC News, ABC News's "PM" with Mark Colvin, CTV News, CBC News, The Toronto Star, Globe and Mail, Ottawa Citizen and the Calgary Herald.
About half a million ...
Over 340 people worldwide have joined WaveCheck's Indiegogo crowdfunding campaign to fund a breakthrough clinical technique for breast cancer that promises to revolutionize the way chemotherapy is monitored.
"Breast Cancer Awareness Month’s positivity makes it easy to overlook the fact that 60 to 70 per cent of chemotherapy treatments fail,” says Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook Health Sciences Centre and co-inventor of WaveCheck with Professor Michael C. Kolios of Ryerson University. “WaveCheck’s technology can tell people with breast ...
Indiegogo campaign to raise funds for North American clinical study during Breast Cancer Awareness Month; 12 artists donate 13 original works worth over $15,000 to support campaign
Toronto, Canada (October 9, 2013) — WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer.
WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer ...
Stem Cell Therapeutics Corp. (TSX-V: SSS), a biopharmaceutical company developing cancer stem cell-related technologies, has signed a definitive license agreement with University Health Network (UHN), Toronto, Canada.
The agreement, developed in collaboration with MaRS Innovation, provides Stem Cell Therapeutics (SCT) with exclusive worldwide rights to an innovative clinical cancer stem cell program.
This announcement builds upon the existing stem cell program agreement between MI, Stem Cell Therapeutics and UHN, which was announced in November 2012.
The initial consideration of $1.6 million for the UHN ...
An early-stage technology that may revolutionize the way burn victims are treated is generating considerable buzz in Toronto media this week.
Globe and Mail reporter Robert Everett-Green wrote about the joint University of Toronto and Sunnybrook Health Sciences Centre project January 20 in "A 3-D machine that prints skin? How burn care could be revolutionized."
Health reporter Beatrice Politi also covered the Bio Printer project for Global News Toronto January 21. Her video segment includes an interview with PhD student Lian Leng and ...